Through a combination of five TAAs (Hsp60, p53, Her2-Fc, NY-ESO-1, and Hsp70) immobilized on an optimized surface chemistry, 82.7% of breast cancer patients were specifically detected. This evidence concerns the gene TP53 and breast carcinoma.